Mayne Pharma Group Limited
ASX: MYX
Mayne Pharma Posts Solid Revenue Growth and Reaffirms Strategic Focus
(Source: TradingView) 3-Month Performance Profile of MYX on a DTF compared to ASX 200 (XJO)
Mayne Pharma reported revenue of about $408 million up 5.07% YOY and a gross margin near 61% indicate modest top-line growth with clear progress on profitability mix, reducing reliance on price‑sensiti
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
